Yong-Xun Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yong-Xun Zhao has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Ze Yang
The Seventh Department of General Surgery, Department of Thyroid Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, China
8 shared publicationsHengtong Han
The Seventh Department of General Surgery, Department of Thyroid Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, China
6 shared publicationsLibin Ma
The Seventh Department of General Surgery, Department of Thyroid Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, China
6 shared publicationsTianying Zhang
The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China
4 shared publicationsTingting Zhang
The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China
4 shared publicationsYating Zhang
The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China
4 shared publications
Latest Publications
- Open Access
- 25 February 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
One of the fastest-growing malignant tumors in the world is thyroid cancer (TC), and there are currently no effective treatments for its aggressive subtypes, such as anaplastic carcinoma and radioactive iodine-refractory differentiated thyroid carcinoma. Recent investigations have shown that DNA methylation and metabolic reprogramming are not independent events, but rather create a closely interconnected, mutually reinforcing network of carcinogenic processes. On the one hand, metabolic reprogramming influences the methylation status of tumor suppressor genes and thyroid function genes by dynamically regulating the activity of DNA methyltransferases and demethylases through important metabolites (such as S-adenosylmethionine, or SAM, and α-KG) and oncogenic signaling pathways (like PI3K/AKT). Conversely, DNA methylation systematically remodels cellular glucose, lipid, and amino acid metabolism by directly silencing metabolic enzyme genes (such as FASN and GLS) and thyroid differentiation markers (such as NIS) to fulfill its proliferative demands. Tumor growth, treatment resistance, and the development of an immunosuppressive microenvironment are all fueled by this ongoing bidirectional interaction, which creates a self-reinforcing oncogenic cycle. As a result, the limitations of earlier discrete debates on DNA methylation or metabolic reprogramming are overcome in this review. To methodically clarify their crosstalk mechanisms, a theoretical framework based on the “DNA methylation-metabolism axis” is suggested. Additionally, it suggests multimodal therapy approaches that focus on this axis. Incorporating biomimetic delivery technologies, combined with epigenetic, metabolic, and immunotherapies, to lay the groundwork for comprehending TC causes and creating targeted treatments.
- 25 February 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Open AccessThe molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
One of the fastest-growing malignant tumors in the world is thyroid cancer (TC), and there are currently no effective treatments for its aggressive subtypes, such as anaplastic carcinoma and radioactive iodine-refractory differentiated thyroid carcinoma. Recent investigations have shown that DNA methylation and metabolic reprogramming are not independent events, but rather create a closely interconnected, mutually reinforcing network of carcinogenic processes. On the one hand, metabolic reprogramming influences the methylation status of tumor suppressor genes and thyroid function genes by dynamically regulating the activity of DNA methyltransferases and demethylases through important metabolites (such as S-adenosylmethionine, or SAM, and α-KG) and oncogenic signaling pathways (like PI3K/AKT). Conversely, DNA methylation systematically remodels cellular glucose, lipid, and amino acid metabolism by directly silencing metabolic enzyme genes (such as FASN and GLS) and thyroid differentiation markers (such as NIS) to fulfill its proliferative demands. Tumor growth, treatment resistance, and the development of an immunosuppressive microenvironment are all fueled by this ongoing bidirectional interaction, which creates a self-reinforcing oncogenic cycle. As a result, the limitations of earlier discrete debates on DNA methylation or metabolic reprogramming are overcome in this review. To methodically clarify their crosstalk mechanisms, a theoretical framework based on the “DNA methylation-metabolism axis” is suggested. Additionally, it suggests multimodal therapy approaches that focus on this axis. Incorporating biomimetic delivery technologies, combined with epigenetic, metabolic, and immunotherapies, to lay the groundwork for comprehending TC causes and creating targeted treatments.
- Open Access
- 31 December 2025
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Misdiagnosed follicular adenoma with 11 year postoperative liver and lung metastases a case report and literature review
Background As the second most common thyroid cancer, the follicular form has a good prognosis, but it is easily confused with follicular adenoma pre-operatively, which often leads to misdiagnosis, delayed treatment, and an increased risk of hematogenous metastasis. The optimization of diagnostic and treatment strategies is crucial for increasing the early diagnosis rate and improving the prognosis. Case presentation A 73-year-old male was misdiagnosed as "follicular adenoma" 11 years previously and the left thyroid adenoma was resected. He was admitted with a confirmed diagnosis of follicular thyroid cancer and multiple metastases to the liver and lungs. A total resection of the left residual thyroid and the right thyroid and isthmus was performed, combined with bilateral central lymph node dissection, and post-operatively, two 131I-NaI 100 mCi treatments for the metastatic foci in the liver and lungs were administered, as well as regularly receiving oral levothyroxine replacement therapy. The one-year follow-up showed no recurrence of the primary foci and a significant reduction in metastatic foci, confirming the effectiveness of the comprehensive treatment program. Conclusion Pre-surgery, follicular thyroid carcinoma is easily confused with follicular adenoma and nodular goiter with non-invasive encapsulated follicular tumors with papillary carcinoma nuclei, and it requires standardized treatment and detection of metastatic foci. Surgery combined with radioiodine is the mainstay of treatment and it is supplemented with levothyroxine replacement therapy. Targeted drugs are available for patients, refractory to radiotherapy. Long-term follow-up is essential to improve the prognosis.
- 31 December 2025
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessMisdiagnosed follicular adenoma with 11 year postoperative liver and lung metastases a case report and literature review
Background As the second most common thyroid cancer, the follicular form has a good prognosis, but it is easily confused with follicular adenoma pre-operatively, which often leads to misdiagnosis, delayed treatment, and an increased risk of hematogenous metastasis. The optimization of diagnostic and treatment strategies is crucial for increasing the early diagnosis rate and improving the prognosis. Case presentation A 73-year-old male was misdiagnosed as "follicular adenoma" 11 years previously and the left thyroid adenoma was resected. He was admitted with a confirmed diagnosis of follicular thyroid cancer and multiple metastases to the liver and lungs. A total resection of the left residual thyroid and the right thyroid and isthmus was performed, combined with bilateral central lymph node dissection, and post-operatively, two 131I-NaI 100 mCi treatments for the metastatic foci in the liver and lungs were administered, as well as regularly receiving oral levothyroxine replacement therapy. The one-year follow-up showed no recurrence of the primary foci and a significant reduction in metastatic foci, confirming the effectiveness of the comprehensive treatment program. Conclusion Pre-surgery, follicular thyroid carcinoma is easily confused with follicular adenoma and nodular goiter with non-invasive encapsulated follicular tumors with papillary carcinoma nuclei, and it requires standardized treatment and detection of metastatic foci. Surgery combined with radioiodine is the mainstay of treatment and it is supplemented with levothyroxine replacement therapy. Targeted drugs are available for patients, refractory to radiotherapy. Long-term follow-up is essential to improve the prognosis.
- Open Access
- 5 November 2025
- Published by Elsevier in Cellular Signalling
- Vol. 138, 112213
Cancer-associated fibroblasts: The "Achilles' Heel" in thyroid tumor progression and therapy
- 5 November 2025
- Published by Elsevier in Cellular Signalling
- Vol. 138, 112213
Open AccessCancer-associated fibroblasts: The "Achilles' Heel" in thyroid tumor progression and therapy
- Open Access
- 8 October 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 24 (1) , 1-22
Exosome-mediated metabolic reprogramming: effects on thyroid cancer progression and tumor microenvironment remodeling
Metabolic reprogramming is one of the fundamental characteristics of thyroid cancer (TC), which meets its energy and biosynthetic demands through mitochondrial dysfunction, glycolysis activation, lipid metabolism imbalance, and glutamine dependency, thereby promoting metastasis and reshaping the immune microenvironment. Exosomes, as extracellular vesicles, play a crucial role in TC by delivering bioactive molecules such as proteins, lipids, and nucleic acids. In the tumor microenvironment (TME) of TC, exosomes secreted by both tumor and non-tumor cells interact with each other, driving metabolic reprogramming and forming a bidirectional regulatory network. This significantly alters the biological characteristics of TC cells, including proliferation, invasion, metastasis, angiogenesis, and the acquisition of drug resistance and immune tolerance, ultimately influencing the process of immune escape in TC. This review systematically summarizes how exosomes in the TME of TC promote tumor progression through metabolic reprogramming, providing new diagnostic and therapeutic strategies for patients with locally advanced, radioiodine-refractory TC.
- 8 October 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 24 (1) , 1-22
Open AccessExosome-mediated metabolic reprogramming: effects on thyroid cancer progression and tumor microenvironment remodeling
Metabolic reprogramming is one of the fundamental characteristics of thyroid cancer (TC), which meets its energy and biosynthetic demands through mitochondrial dysfunction, glycolysis activation, lipid metabolism imbalance, and glutamine dependency, thereby promoting metastasis and reshaping the immune microenvironment. Exosomes, as extracellular vesicles, play a crucial role in TC by delivering bioactive molecules such as proteins, lipids, and nucleic acids. In the tumor microenvironment (TME) of TC, exosomes secreted by both tumor and non-tumor cells interact with each other, driving metabolic reprogramming and forming a bidirectional regulatory network. This significantly alters the biological characteristics of TC cells, including proliferation, invasion, metastasis, angiogenesis, and the acquisition of drug resistance and immune tolerance, ultimately influencing the process of immune escape in TC. This review systematically summarizes how exosomes in the TME of TC promote tumor progression through metabolic reprogramming, providing new diagnostic and therapeutic strategies for patients with locally advanced, radioiodine-refractory TC.
- Open Access
- 25 September 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1880 (6) , 189459
Oncogenic mutation-driven metabolism-immunity regulatory axis: Potential prospects for thyroid cancer precision therapy
- 25 September 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1880 (6) , 189459
Open AccessOncogenic mutation-driven metabolism-immunity regulatory axis: Potential prospects for thyroid cancer precision therapy
- Open Access
- 8 September 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (9) , 1292
The Emerging Role of Mitochondrial Dysfunction in Thyroid Cancer: Mediating Tumor Progression, Drug Resistance, and Reshaping of the Immune Microenvironment
As the hub of energy metabolism and the cell’s fate arbiter, mitochondria are essential for preserving cellular homeostasis and converting it from pathological states. Therefore, through mechanisms that drive metabolic reprogramming, oxidative stress, and apoptosis resistance, mitochondrial dysfunction (including mitochondrial DNA mutations, mitochondrial dynamics imbalance, mitochondrial autophagy abnormalities, mitochondrial permeability abnormalities, and metabolic disorder) can promote the progression of thyroid cancer (TC), resistance to treatment, and reshaping of the immune microenvironment. This article reviews the molecular mechanisms and characteristic manifestations of mitochondrial dysfunction in TC. It focuses on providing a summary of the main strategies currently used to target the mitochondria, such as dietary intervention and targeted medications like curcumin, as well as the clinical translational value of these medications when used in conjunction with current targeted therapies for TC and radioactive iodine (RAI) therapy in patients with advanced or RAI-refractory TC who rely on targeted therapies. The application prospects and existing challenges of emerging therapeutic methods, such as mitochondrial transplantation, are also discussed in depth, aiming to provide new perspectives for revealing the molecular mechanisms by which mitochondrial dysfunction drives the progression of TC, drug resistance, and the reshaping of its immune microenvironment, as well as providing new diagnostic and therapeutic strategies for patients with advanced or RAI-refractory TC who are reliant on targeted therapies.
- 8 September 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (9) , 1292
Open AccessThe Emerging Role of Mitochondrial Dysfunction in Thyroid Cancer: Mediating Tumor Progression, Drug Resistance, and Reshaping of the Immune Microenvironment
As the hub of energy metabolism and the cell’s fate arbiter, mitochondria are essential for preserving cellular homeostasis and converting it from pathological states. Therefore, through mechanisms that drive metabolic reprogramming, oxidative stress, and apoptosis resistance, mitochondrial dysfunction (including mitochondrial DNA mutations, mitochondrial dynamics imbalance, mitochondrial autophagy abnormalities, mitochondrial permeability abnormalities, and metabolic disorder) can promote the progression of thyroid cancer (TC), resistance to treatment, and reshaping of the immune microenvironment. This article reviews the molecular mechanisms and characteristic manifestations of mitochondrial dysfunction in TC. It focuses on providing a summary of the main strategies currently used to target the mitochondria, such as dietary intervention and targeted medications like curcumin, as well as the clinical translational value of these medications when used in conjunction with current targeted therapies for TC and radioactive iodine (RAI) therapy in patients with advanced or RAI-refractory TC who rely on targeted therapies. The application prospects and existing challenges of emerging therapeutic methods, such as mitochondrial transplantation, are also discussed in depth, aiming to provide new perspectives for revealing the molecular mechanisms by which mitochondrial dysfunction drives the progression of TC, drug resistance, and the reshaping of its immune microenvironment, as well as providing new diagnostic and therapeutic strategies for patients with advanced or RAI-refractory TC who are reliant on targeted therapies.
- Open Access
- 26 November 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 144, 113702
Emerging role of metabolic reprogramming in the immune microenvironment and immunotherapy of thyroid cancer
- 26 November 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 144, 113702
Open AccessEmerging role of metabolic reprogramming in the immune microenvironment and immunotherapy of thyroid cancer
- 6 July 2023
- Published by Springer Nature in Biochemical Genetics
- Vol. 62 (2) , 718-740
TET1 is a Diagnostic and Prognostic Biomarker Associated with Immune Infiltration in Papillary Thyroid Cancer
To investigate the function of ten-eleven translocation 1 (TET1) and its underlying mechanism in papillary thyroid cancer (PTC). Using the RNA-Seq data based on GDC TCGA, we analyzed the gene expression pattern of TET1 in PTC. Immunohistochemistry was carried out to assess the TET1 protein level. Then, its diagnostic and prognostic functions were determined by various bioinformatics approaches. Enrichment analysis was performed to explore the potential pathways in which TET1 is mainly involved. Finally, the immune cell infiltration analysis was conducted and the association of TET1 mRNA expression with the expression levels of immune checkpoints, tumor mutation burden (TMB) score, microsatellite instability (MSI) score, and cancer stem cells (CSC) score was examined. TET1 expression was lower in PTC tissues compared with that in normal tissues (P < 0.01). Besides, TET1 had a certain value in diagnosing PTC, and low-TET1 mRNA expression led to favorable disease-specific survival (DSS) (P < 0.01). The enrichment analysis revealed autoimmune thyroid disease and cytokine-cytokine receptor interaction were the consistent pathways in which TET1 participated. TET1 was negatively correlated with the Stromal score and Immune score. The different proportions of immune cell subtypes were observed between high- and low-TET1 expression groups. Interestingly, TET1 mRNA expression was inversely related to the expression levels of immune checkpoints, and TMB, MSI, and CSC scores. TET1 might be a robust diagnostic and prognostic biomarker for PTC. TET1 affected the DSS of PTC patients possibly through the regulation of immune-related pathways and tumor immunity.
- 6 July 2023
- Published by Springer Nature in Biochemical Genetics
- Vol. 62 (2) , 718-740
TET1 is a Diagnostic and Prognostic Biomarker Associated with Immune Infiltration in Papillary Thyroid Cancer
To investigate the function of ten-eleven translocation 1 (TET1) and its underlying mechanism in papillary thyroid cancer (PTC). Using the RNA-Seq data based on GDC TCGA, we analyzed the gene expression pattern of TET1 in PTC. Immunohistochemistry was carried out to assess the TET1 protein level. Then, its diagnostic and prognostic functions were determined by various bioinformatics approaches. Enrichment analysis was performed to explore the potential pathways in which TET1 is mainly involved. Finally, the immune cell infiltration analysis was conducted and the association of TET1 mRNA expression with the expression levels of immune checkpoints, tumor mutation burden (TMB) score, microsatellite instability (MSI) score, and cancer stem cells (CSC) score was examined. TET1 expression was lower in PTC tissues compared with that in normal tissues (P < 0.01). Besides, TET1 had a certain value in diagnosing PTC, and low-TET1 mRNA expression led to favorable disease-specific survival (DSS) (P < 0.01). The enrichment analysis revealed autoimmune thyroid disease and cytokine-cytokine receptor interaction were the consistent pathways in which TET1 participated. TET1 was negatively correlated with the Stromal score and Immune score. The different proportions of immune cell subtypes were observed between high- and low-TET1 expression groups. Interestingly, TET1 mRNA expression was inversely related to the expression levels of immune checkpoints, and TMB, MSI, and CSC scores. TET1 might be a robust diagnostic and prognostic biomarker for PTC. TET1 affected the DSS of PTC patients possibly through the regulation of immune-related pathways and tumor immunity.